ライフサイエンスコーパス: Taxotere

1 for Procet 8, in comparison to 2826ng/mL for Taxotere.

2 in prostate cancer cells exposed to DIM and Taxotere.

3 tered mitosis and were selectively killed by Taxotere.

4 ected normal FDC-P1 hematopoietic cells from Taxotere.

5 of Adriamycin prevented cell death caused by Taxotere.

6 le of docetaxel in cancer patients receiving Taxotere.

7 ration of the commercial docetaxel solution, Taxotere.

8 to a C9-ketone which is present in Taxol and Taxotere.

9 mpared with corresponding cells treated with taxotere.

10 Taxotere 0.001 microM-induced JNK activation started aft

11 bations were synergistic with subsequent 1-h Taxotere 0.01, 0.1 and 1.0 microM incubations in breast

12 Activation of JNK by Taxotere 0.01, 0.1 and 1.0 microM was observed at 24 h i

13 ion was predicted to be 2.6 times lower than Taxotere (775 vs. 2017hxng/mL, respectively), resulting

14 In contrast, docetaxel (Taxotere), a closely related antineoplastic agent, did n

15 Taxotere, a potent analog of taxol, did not induce any o

16 nt levels for their sensitivity to Taxol and Taxotere, a synthetic taxoid.

17 may provide a benefit beyond treatment with Taxotere alone in advanced, metastatic breast cancer.

18 Taxotere, an analogue that stabilizes microtubules as po

19 When compared with Taxotere, an equivalent dose of docetaxel administered i

20 Pharmacokinetic modeling of Taxotere and Procet 8 plasma concentrations, and their a

21 MP470 synergizes with docetaxel (taxotere) and is cytotoxic to GIST cells.

22 rmination of the anticancer agent docetaxel (Taxotere) and its formulation vehicle polysorbate 80 (Tw

23 correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fol

24 Tumors from the Cancer Research UK Taxotere as Adjuvant Chemotherapy phase III trial were t

25 ctivation and PARP cleavage induced by 30 nM Taxotere at 48 h were reversed by curcumin, PD169316 and

26 utic agents paclitaxel (Taxol) or docetaxel (Taxotere) both in vitro and in vivo.

27 microtubule-targeted agents vincristine and taxotere but not with 5-fluorouracil or doxorubicin.

28 Taxol and taxotere each induced PGHS-2 expression in human monocyt

29 ant microtubule-disrupting agents, including taxotere, epothilone B, discodermolide, vincristine, 2-m

30 rug release estimates for the fast releasing Taxotere formulation demonstrated accuracy deviation and

31 Paclitaxel (Taxol) and docetaxel (Taxotere) have been shown to inhibit angiogenesis at low

32 izing agents (MTPAs), notably paclitaxel and taxotere, have come to occupy a central role in the trea

33 serum responded only to LPS, not to taxol or taxotere, implying that they act independently of the LP

34 arked enhanced absorption compared with oral Taxotere in minipigs, resulting in relative bioavailabil

35 Also, Adriamycin prevented the effects of Taxotere in normal human lymphocytes.

36 by DIM enhanced the therapeutic efficacy of Taxotere in prostate cancer in general, which could be u

37 Treatment with paclitaxel or taxotere increased DR4 and/or DR5 protein levels (up to

38 on of the effects of taxol and its analogue, taxotere, indicates that taxotere is capable of inducing

39 We observed that DIM enhanced Taxotere-induced apoptotic death in both cell lines.

40 These data demonstrate the potentiation of Taxotere-induced cell death by ATRA pretreatment in brea

41 days prior to Taxotere treatment potentiated Taxotere-induced JNK activation 24 and 48 h later, an ef

42 t in the chemosensitization of HRPC cells to Taxotere-induced killing.

43 All three inhibitors reversed Taxotere-induced phosphorylation of Bcl-2.

44 Dual therapy with P1pal-7 and Taxotere inhibits the growth of MDA-MB-231 xenografts by

45 Taxotere is a cytotoxin effective in treating breast and

46 l and its analogue, taxotere, indicates that taxotere is capable of inducing bcl2 phosphorylation and

47 Taxotere kills cells in mitosis.

48 roved anticancer activity compared with i.v. Taxotere, observed in the metastatic lung cancer model i

49 The Procet 8 and Taxotere plasma profiles, and associated docetaxel hydro

50 lling 2 weeks after first dose of docetaxel (Taxotere(R)) and trastuzumab (Herceptin(R)) chemotherapy

51 xic optic neuropathy secondary to docetaxel (Taxotere(R)) chemotherapy.

52 releasing commercial docetaxel formulation, Taxotere(R), and a delayed releasing nanomicellar formul

53 (Taxol, Bristol-Myers Squibb) and docetaxel (Taxotere, Rhone-Poulenc Rhorer).

54 vity, safety, and tolerability of docetaxel (Taxotere: Rhone-Poulenc Rorer Pharmaceuticals Inc, Colle

55 e in vitro activity of the taxoid docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) in primar

56 Because docetaxel (Taxotere, RP 56976; Rhone-Poulenc Rorer, Antony, France)

57 PD90598 potentiated the cytotoxic effect of Taxotere selectively in Raf-1-transformed FDC-P1 leukemi

58 In contrast, Taxotere selectively killed MRP1-expressing leukemia cel

59 the synergistic cytotoxicity of P1pal-7 and Taxotere, suggesting that Akt is a critical component of

60 When combined, laulimalide and docetaxel (Taxotere) synergistically inhibited migration and tubule

61 ts such as paclitaxel (Taxol) and docetaxel (Taxotere) than those that do not overexpress HER-2/neu.

62 hance the therapeutic activity of docetaxel (Taxotere), the most commonly used drug for the treatment

63 Furthermore, whereas none of the Taxotere-treated mice survived longer than 34 days, 33%

64 ls with ATRA 0.01 microM for 3 days prior to Taxotere treatment potentiated Taxotere-induced JNK acti

65 e effect of DIM alone or in combination with Taxotere using LNCaP and C4-2B prostate cancer cells.

66 observed that paclitaxel (Taxol), docetaxel (Taxotere), vinblastine, vincristine, nocodazole, and col

67 g, Procet 8, and commercial DTX formulation, Taxotere, was conducted in bile duct cannulated rats.

68 mycin-resistant cancer cells with Docetaxel (Taxotere), while protecting parental (Adriamycin-sensiti

69 ceptor antagonist (ABT-627; Atrasentan) with Taxotere will be superior in inducing apoptosis in vitro